Keyphrases
Anticancer Agents
100%
Drug Design
100%
Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)
100%
Oxindole
100%
Pharmacophore-based
100%
Drug Synthesis
100%
Anticancer Drugs
50%
Binding Site
50%
Tumor
25%
Mode of Action
25%
Cell Migration
25%
Signaling Molecules
25%
Flow Cytometry
25%
Moderate to Severe
25%
Apoptosis
25%
Weight Loss
25%
Enzyme Inhibition
25%
Solid Tumors
25%
2 Receptor
25%
Cancer Cell Lines
25%
Tumor Growth
25%
Western Blot
25%
Clinical Effect
25%
Sigma Phase
25%
Cytotoxicity Test
25%
Design Approach
25%
Homology Modeling
25%
TRK Inhibitors
25%
Erlotinib
25%
IC50 Value
25%
High Selectivity
25%
Matrix metalloproteinase-9 (MMP-9)
25%
Safe Profile
25%
Selective Toxicity
25%
In Vitro Inhibition
25%
Moderate Activity
25%
Less Toxic
25%
Lethal Dose 50 (LD50)
25%
Phase Following
25%
Sunitinib
25%
Synthesized Compounds
25%
Conformational Switch
25%
GI50
25%
Derivative-based
25%
A431
25%
EGFR Receptor
25%
Vandetanib
25%
2H-benzimidazole
25%
Dual Inhibitor
25%
A431 Cell Line
25%
Pharmacology, Toxicology and Pharmaceutical Science
Anticarcinogen
100%
Drug Development
100%
Epidermal Growth Factor Receptor
100%
Vasculotropin Receptor 2
100%
Oxindole
100%
Drug Synthesis
100%
Neoplasm
50%
Side Effect
50%
Binding Site
50%
Flow Cytometry
25%
Western Blot
25%
IC50
25%
Malignant Neoplasm
25%
Cytotoxicity
25%
Enzyme Inhibition
25%
Solid Malignant Neoplasm
25%
Tumor Growth
25%
Erlotinib
25%
Gelatinase B
25%
Sunitinib
25%
Benzimidazole
25%
Vandetanib
25%